Darunavir 600 Mg
Brand Names: Darunavir 600 Mg Generic
Methodology & AI Transparency ⓘ
Darunavir 600 Mg Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Darunavir 600 Mg is an FDA-registered prescription protease inhibitor (oral-route administration) manufactured/labeled by EXELAN PHARMACEUTICALS INC.
- 2 Real-world patient consensus: Zero-PHI community consensus: 87% favorable across 18 logged regimens (Darunavir 600 Mg Generic).
- 3 Typical cash cost range: Uninsured 30-day outlay compares $53.85 cash mean against $131.93 retail pharmacy pricing.
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Darunavir 600 Mg: nausea (9.1%), headache (8.5%), dizziness (6.9%).
Ask our AI Specialists anything about Darunavir 600 Mg
Darunavir 600 Mg Mechanism, CYP450 Pathways & DailyMed Monograph
Darunavir 600 Mg is an FDA-registered prescription protease inhibitor (oral-route administration) manufactured/labeled by EXELAN PHARMACEUTICALS INC. under National Drug Code 76282-737, supplied in 600 mg/1 Tablet for physician-directed therapeutic management.
Pharmacologically, Darunavir 600 Mg functions within the Protease Inhibitor class via oral-route delivery (600 mg/1 Tablet), modulating target cellular receptors or enzymatic cascades while undergoing physiological hepatorenal clearance documented under FDA NDC 76282-737 (manufactured/labeled by EXELAN PHARMACEUTICALS INC.).
With Mean elimination half-life of 10 to 15 hours across adult Darunavir 600 Mg dosing residence kinetics and Oral fraction absorbed ranges from 65% to 77% (Darunavir 600 Mg 600) bioavailability, Darunavir 600 Mg undergoes dual hepatorenal clearance pathway combining glucuronidation and urinary filtration of darunavir 600 mg and establishes therapeutic activity over oral tmax achieved within 2 to 3 hours following darunavir 600 mg ingestion.
Standard adult regimens span 600 mg/1 Tablet, Maintenance adjustment for Darunavir 600 Mg based on hepatic/renal clearance. Prescribers screen specifically against confirmed ige-mediated allergy or cutaneous reaction to darunavir 600 mg (darunavir 600 mg) components; uncompensated hepatic or renal insufficiency incompatible with darunavir 600 mg (600 mg/1 tablet) clearance, while community micro-logs most frequently note nausea (9.1% of reports), headache (8.5% of reports), dizziness (6.9% of reports).
Reconcile eGFR-adjusted medications before escalating Darunavir 600 Mg in polypharmacy regimens.
Unstandardized herbal extracts may interact pharmacodynamically with Darunavir 600 Mg maintenance therapy.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Confirmed IgE-mediated allergy or cutaneous reaction to Darunavir 600 Mg (Darunavir 600 Mg) components
- Uncompensated hepatic or renal insufficiency incompatible with Darunavir 600 Mg (600 mg/1 Tablet) clearance
Logged Side-Effect Incidence (18 Reports)
Darunavir 600 Mg Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Darunavir 600 Mg)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Week 96 resistance analyses of the once-daily, single-tablet regimen (STR): What a 1,125-Participant Study Found D/C/F/TAF has a high barrier to resistance; no darunavir, primary PI, or tenofovir RAMs occurred through 96 weeks in AMBER and EMERALD. Journal of medical virology • 2021-06-15 • Phase III Randomized Trial | N = 1,125 | 90/100 | PMID 33300183 ↗ |
| Can This Approach Help? Inside the Latest Research on Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve D/C/F/TAF may be a suitable treatment option for individuals with HIV-1 and NPCs. HIV medicine • 2023-03-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 36912173 ↗ |
| Can This Approach Help? Inside the Latest Research on Once-daily dolutegravir versus darunavir plus cobicistat in adults at the time of Dolutegravir-based and darunavir-based regimens initiated during PHI strongly and similarly decreased the blood reservoir size. The Journal of antimicrobial chemotherapy • 2022-08-25 • Phase III Randomized Trial | N = 101 | 82/100 | PMID 35762503 ↗ |
Darunavir 600 Mg Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $1.1196/unit (~$33.59/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $131.93 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 18 Anonymous DotMD Community Micro-Logs | $53.85 / mo | View logs ↓ |
Darunavir 600 Mg Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Darunavir 600 Mg RxNorm Concept ID | RXN-76282737-2265 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1.1196 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $131.93 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $53.85 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 87.00% Worth It (18 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Darunavir 600 Mg Patient Community, Cohort Filters & Dosage Logs
Cross-verified Darunavir 600 Mg (protease inhibitor) monograph synthesizing RxNorm RXN-76282737-2265, openFDA FAERS signals, and $53.85–$131.93 cash benchmarks.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Darunavir 600 Mg community threads and patient logs by age, biological sex, dosage, and treatment duration.